

## APC Human OX40 (CD134) Protein (C-Fc-Avi)

<b>Catalog Number:</b>	818203, 818204
<b>Size:</b>	25 ug, 100 ug
<b>Target Name:</b>	TNFRSF4, OX40, CD134, OX40L receptor
<b>Regulatory Status:</b>	RUO

### PRODUCT DETAILS

---

<b>Application:</b>	Flow Cytometry
<b>Format:</b>	Liquid, APC
<b>Expression Host:</b>	CHO
<b>Species:</b>	Human
<b>Sources:</b>	Recombinant Human OX40 (Lue29-Ala216 ) with C-terminus Fc-Avi-tag is expressed in CHO cell and conjugated to APC.
<b>Accession Number:</b>	P43489
<b>Molecular Weight:</b>	The protein has a predicted molecular weight of 48.5 kDa. Under DTT-reducing conditions, it migrates at approximately 65 kDa on SDS-PAGE prior to conjugation.
<b>Affinity Tag:</b>	C-Fc-Avi
<b>Formulation:</b>	1xPBS buffer, pH7.4, 0.09% NaN3 with a carrier protein
<b>Endotoxin level:</b>	Not tested
<b>Protein Concentration:</b>	25µg size is bottled at 0.1mg/mL concentration. 100 µg size is bottled at lot specific concentration.
<b>Storage and Handling:</b>	Briefly centrifuge the vial upon receipt. An unopened vial may be stored at 2-8°C for up to six months.

### BACKGROUND INFORMATION

---

OX40 (CD134) and its ligand OX40L (CD252), both part of the TNF receptor superfamily, play a key role in immune regulation. Their interaction is essential for T-cell expansion, survival, and cytokine production, influencing T cells, antigen-presenting cells, NK cells, and NKT cells. OX40-OX40L signaling helps break immune tolerance in malignancies, promoting antitumor immunity, and is also involved in the development of inflammatory and autoimmune diseases. Due to these regulatory effects, the OX40-OX40L pathway is a promising target for therapeutic interventions in both cancer and infectious diseases, with OX40 stimulation showing potential for therapeutic immunization strategies.